Verma Rajanshu, Dhamija Radhika, Batts Donald H, Ross Stephen C, Loehrke Mark E
Department of Internal Medicine, Michigan State University/KCMS 1000 Oakland Dr, Kalamazoo, Michigan 49008 USA.
Cases J. 2009 Jul 20;2:8063. doi: 10.4076/1757-1626-2-8063.
Moxifloxacin is a newer-generation synthetic fluoroquinolone that is used for treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community acquired pneumonia, intra-abdominal infections and skin/skin structure infections. We describe a case of fatal hepatotoxicity caused by Moxifloxacin in a 72-year-old man. He presented with jaundice and epigastric tenderness that started one week after being treated for acute exacerbation of his chronic bronchitis with Moxifloxacin by his primary care physician. He was admitted to intensive care unit for close monitoring. His labs showed marked elevation in liver enzymes and bilirubin. His condition continued to deteriorate in intensive care unit despite supportive care. Acute hepatic failure which resulted in his death was attributed to idiosyncratic reaction to Moxifloxacin.
莫西沙星是新一代合成氟喹诺酮类药物，用于治疗急性细菌性鼻窦炎、慢性支气管炎急性加重、社区获得性肺炎、腹腔内感染以及皮肤/皮肤结构感染。我们报告一例72岁男性因莫西沙星导致致命肝毒性的病例。他在初级保健医生用莫西沙星治疗慢性支气管炎急性加重一周后出现黄疸和上腹部压痛。他被收入重症监护病房进行密切监测。他的实验室检查显示肝酶和胆红素显著升高。尽管给予了支持治疗，但他在重症监护病房的病情仍继续恶化。导致其死亡的急性肝衰竭归因于对莫西沙星的特异质性反应。
